Minshu Yu

Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses

Jung Min Lee, John L. Hays, Christina M. Annunziata et al. · JNCI Journal of the National Cancer Institute · 2014 · 183 citations · Full text

Medicine, Oncology, Pharmacology +14

Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2

Christina M. Annunziata, Amanda J. Walker, Lori M. Minasian et al. · Clinical Cancer Research · 2010 · 84 citations · Full text

Medicine, Oncology, Pharmacology +17

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases <i>in vitro</i> toxicity of PARP inhibition by preventing Rad51 foci formation in <i>BRCA</i> wild type high-grade serous ovarian cancer

Ethan Brill, Takuhei Yokoyama, Jayakumar R. Nair et al. · Oncotarget · 2017 · 79 citations · Full text

Medicine, Oncology, Pharmacology +17

Differential Expression of Alternatively Spliced Forms of MAP4: A Repertoire of Structurally Different Microtubule-Binding Domains

Steven J. Chapin, Chia-Man Lue, Minshu Yu et al. · Biochemistry · 1995 · 77 citations

Life Sciences, Biochemistry, Molecular Biology +9

Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers

Jasmine J. Han, Minshu Yu, Nicole Houston et al. · Gynecologic Oncology · 2010 · 66 citations

Medicine, Molecular Biology, Oncology +12